高级别胶质瘤诊断与治疗反应评估中的先进影像:AJR专家小组叙述性综述
该AJR专家小组叙述性综述探讨了先进MRI和PET技术用于成人型高级别胶质瘤治疗后反应评估的现状,聚焦当前实践中的临床争议。讨论的技术包括DWI、扩散张量成像、灌注MRI(DSC、DCE、ASL)、MRS(含2HG浓度)、葡萄糖和氨基酸PET及酰胺质子转移成像,并介绍了更新的RANO标准。专家组基于充分临床证据推荐常规反应评估应包括灌注MRI,尤其鉴于共识推荐的DSC-MRI协议已建立。
要点
- 专家组推荐高级别胶质瘤治疗后常规反应评估应包括灌注MRI,尤其推荐共识DSC-MRI协议。
- DWI、扩散张量成像、灌注MRI、MRS(含2HG)、葡萄糖和氨基酸PET及酰胺质子转移成像可补充常规MRI。
- 更新版RANO标准已提出,用于治疗反应评估。
核心结论
- 基于充分支持的临床证据,专家组支持推荐高级别胶质瘤治疗后常规反应评估应包括灌注MRI,尤其鉴于共识推荐的DSC-MRI协议已建立。
研究设计与样本
- AJR专家小组叙述性综述,探讨先进MRI和PET技术用于成人型高级别胶质瘤治疗后反应评估的现状,聚焦当前实践中的持续临床争议。
关键影像表现/征象
- 先进MRI和PET技术可辅助鉴别复发肿瘤与治疗后效应。
- 讨论的技术包括DWI和扩散张量成像、灌注MRI(DSC、DCE、ASL)、MRS(含2HG浓度评估)、葡萄糖和氨基酸PET及酰胺质子转移成像。
诊断标准与关键数值
- 文章呈现了更新版神经肿瘤学反应评估(RANO)标准。
- 专家组推荐常规反应评估应包括灌注MRI,尤其鉴于共识推荐的DSC-MRI协议已建立。
- 已发表研究支持2HG MRS和氨基酸PET,但这些技术的广泛采用可能需要增加可用性(针对2HG MRS)或增加美国保险资助(针对氨基酸PET)。
临床应用与阅片要点
- 专家组推荐高级别胶质瘤治疗后常规反应评估应包括灌注MRI。
- 2HG MRS和氨基酸PET获得已发表研究支持,但广泛采用可能需增加可用性或保险资助。
- 综述最后提出一系列作者小组的共识意见,集中于将先进影像技术整合进治疗后监测方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This AJR Expert Panel Narrative Review explores the current status of advanced MRI and PET techniques for the posttherapeutic response assessment of high-grade adult-type gliomas, focusing on ongoing clinical controversies in current practice. Discussed techniques that complement conventional MRI and aid the differentiation of recurrent tumor from posttreatment effects include DWI and diffusion-tensor imaging; perfusion MRI techniques including dynamic susceptibility contrast (DSC), dynamic contrast-enhanced, and arterial spin labeling MRI; MR spectroscopy (MRS) including assessment of 2-hydroxyglutarate (2HG) concentration; glucose- and amino acid (AA)-based PET; and amide proton transfer imaging. Updated criteria for the Response Assessment in Neuro-Oncology are presented. Given the abundant supporting clinical evidence, the panel supports a recommendation that routine response assessment after high-grade glioma treatment should include perfusion MRI, particularly given the development of a consensus recommended DSC-MRI protocol. Although published studies support 2HG MRS and AA PET, these techniques' widespread adoption will likely require increased availability (for 2HG MRS) or increased insurance funding in the United States (for AA PET). The review concludes with a series of consensus opinions from the author panel, centered on the clinical integration of the advanced imaging techniques into posttreatment surveillance protocols.
引用
- Hu LS, Smits M, Kaufmann TJ, et al. Advanced Imaging in the Diagnosis and Response Assessment of High-Grade Glioma: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2025. PMID: 38477525. doi:10.2214/AJR.23.30612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。